Post

EU inches closer to new pharma legislation amid competitiveness drive

Pharmaceutical companies marketing products in Europe could be set for a commercial boost, after legislators have agreed on a new …
Biopharma’s 2025 M&A boom: Dealmaking surges as patent pressures intensify

Even with Johnson & Johnson’s (J&J) $14.6bn buyout of Intra-Cellular Therapies in January setting a strong deal-making tone, 2025 still …
China’s NMPA approves Sanofi’s rare haematologic disease treatments

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease treatments, Qfitlia (fitusiran) and Cablivi (caplacizumab), …
Zealand Pharma and OTR to develop metabolic disease therapeutics

Zealand Pharma and OTR Therapeutics have signed a strategic collaboration and licence agreement aimed at jointly discovering and developing therapies …
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn

Novartis has teamed up with AI-led biotech Relation Therapeutics in a deal worth up to approximately $1.7bn to discover and …

Moderna signs deal worth up to $503m with Nanexa

Moderna has entered a licence agreement with Nanexa to add tailored release profiles to its injectable drugs. According to the contract, …
UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments

The UK Government has cut its innovative medicine rebate rate by more than a third in a move likely to …
Pfizer plans job cuts in Switzerland to reduce expenses

Pfizer is set to cut jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by …
Boehringer’s Jascayd gains China’s NMPA approval for PPF

China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd (nerandomilast) to treat progressive pulmonary fibrosis (PPF). The …
Formation Bio gains global rights to Lynk Pharma’s TYK2 inhibitor

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006, a highly selective tyrosine kinase 2 (TYK2) …
Crenolanib delivers incremental benefit in FLT3/NPM1 co-mutated AML

Arog Pharmaceuticals presented new results from a Phase III trial at the American Society of Hematology (ASH) Annual Meeting 2025, …
Cell and gene therapy investment strategy pivots as funding dries up

Companies looking to push into the gene therapy (CGT) sector are navigating a more selective funding landscape amid a wider …
Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility

American pharmaceutical giant Eli Lilly has tapped Huntsville, Alabama, as the location for its third orforglipron manufacturing facility. Set to enter …
Formycon and Zydus sign exclusive agreement for FYB206 supply

Formycon and Zydus Lifesciences have entered an exclusive licensing and supply agreement for FYB206, a biosimilar of MSD’s Keytruda (Pembrolizumab), …
ASH 2025: golcadomide + rituximab combo shows standout potential in R/R FL

Bristol Myers Squibb’s golcadomide, a first-in-class, oral CELMoD (cereblon E3 ligase modulator), has shown compelling activity as monotherapy and in …